HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
 3,335.00
 -60.00 (-1.77%)
  Oct 31, 2025, 3:30 PM KST
HLB Therapeutics Revenue
HLB Therapeutics had revenue of 15.67B KRW in the quarter ending June 30, 2025, with 34.38% growth. This brings the company's revenue in the last twelve months to 61.23B, up 3.54% year-over-year. In the year 2024, HLB Therapeutics had annual revenue of 54.93B with 4.45% growth.
Revenue (ttm) 
 61.23B
Revenue Growth 
 +3.54%
P/S Ratio 
 4.66
Revenue / Employee 
 1.25B
Employees 
 49
Market Cap 
285.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 54.93B | 2.34B | 4.45% | 
| Dec 31, 2023 | 52.59B | 10.19B | 24.03% | 
| Dec 31, 2022 | 42.40B | -1.18B | -2.72% | 
| Dec 31, 2021 | 43.59B | 656.63M | 1.53% | 
| Dec 31, 2020 | 42.93B | -16.04B | -27.20% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| Hanmi Pharm. | 1.47T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B |